Alchemia Announces Initiation of Phase II Trial in Small Cell Lung Cancer
9/12/2011 10:27:54 AM
BRISBANE, Australia--(BUSINESS WIRE)--Alchemia Limited (ASX:ACL), today announced the initiation of recruitment for a Phase II clinical study of its lead cancer drug HA-Irinotecan in Small Cell Lung Cancer (SCLC). Two patients have received their first doses of therapy. This investigator sponsored trial is being conducted at Monash Cancer Centre, Southern Health and Peninsula Oncology Centre in Melbourne, Victoria.
comments powered by